Opthea to Host Opinion Leader Event on Sozinibercept
Ticker: OPTEY · Form: 6-K · Filed: Mar 19, 2024 · CIK: 1815620
Sentiment: neutral
Topics: clinical-trial, drug-development, ophthalmology
TL;DR
Opthea hosting expert event April 3rd for its wet AMD drug sozinibercept.
AI Summary
Opthea Limited announced on March 19, 2024, that it will host an opinion leader event on April 3, 2024, to discuss sozinibercept (OPT-302) for the treatment of wet age-related macular degeneration. The event will feature key opinion leaders in ophthalmology who will share their insights on the potential of sozinibercept.
Why It Matters
This event could provide crucial insights into the clinical development and potential market impact of Opthea's lead drug candidate, sozinibercept, for a significant unmet medical need.
Risk Assessment
Risk Level: medium — The company is in the clinical development phase for a drug, which carries inherent risks related to trial outcomes and regulatory approval.
Key Players & Entities
- Opthea Limited (company) — Registrant
- sozinibercept (OPT-302) (drug) — Lead drug candidate
- wet age-related macular degeneration (disease) — Indication for sozinibercept
- April 3, 2024 (date) — Date of opinion leader event
- March 19, 2024 (date) — Filing date
FAQ
What is the purpose of the opinion leader event?
The event is to discuss sozinibercept (OPT-302) in the context of treating wet age-related macular degeneration and to feature insights from key opinion leaders in ophthalmology.
When will the opinion leader event take place?
The event is scheduled for April 3, 2024.
What is the drug being discussed at the event?
The drug being discussed is sozinibercept, also known as OPT-302.
What condition is sozinibercept intended to treat?
Sozinibercept is being discussed for the treatment of wet age-related macular degeneration.
What type of filing is this 6-K report?
This is a Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Stats: 160 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-03-19 06:06:29
Filing Documents
- opt_kol_event.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 36KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-033139.txt ( ) — 227KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 03/19/2024